COX-2 inhibitors at the 8th International Conference of the Inflammation Research Association.
An intensive search is underway for novel selective inhibitors of cyclo-oxygenase (COX)-2. These compounds promise to be potent anti-inflammatory agents with little gastrointestinal intolerance. Meloxicam, with some selectivity for COX-2, is already marketed, and at least two companies are carrying out clinical studies with selective inhibitors. A variety of potential successor compounds were presented at the 8th International Conference of the Inflammation Research Association (IRA) in Hershey, PA on 27-31 October 1996.
Parnham
M J
MJ
Parnham Advisory Services, Von-Guericke-Allee 4, D-53125 Bonn, Germany.